Comparison

EphB4 Antibody

Item no. E10-20073
Manufacturer Enogene
Amount 100 ug/100 ul
Quantity options 100 ug/100 ul 100 ug/100 ul 100 ul 50 ul
Category
Type Antibody
Format Liquid
Applications WB, IHC, ELISA
Specific against Human (Homo sapiens)
Host Mouse
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias HTK, MYK1, TYRO11
Similar products EphB4
Available
Manufacturer - Applications
WB, IHC, ELISA. Not yet tested in other applications. Determining optimal working dilutions by titration test.
Manufacturer - Conjugate / Tag
This antibody is also available with the following conjugates:
AF350, AF405L, AF405M, AF405S, AF488, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF635, AF647, AF680, AF700, AF750, AF790, APC, AP, Biotin, Cy3, Cy5.5, Cy5, Cy7, FITC, HRP, PE, Magnetic beads (1 um, 2.8 um, 3 um, 4.5 um, 5 um, 10 um, 15 um, 20 um, 30 um, or different size option)
Please contact sales@hoelzel.de for pricing and availability.
Storage Conditions
Store at 4C, for long term storage, store at -20C
Immunogen
Purified recombinant fragment of EphB4 expressed in E. Coli.
Research Area
Autophagy antibody, Cancer, Cardiovascular, Cell Biology, Epigenetics and Nuclear Signaling, Developmental Biologys, Immunology, Drug Discovery Products, Metabolism, Neuroscience, Signal Transduction, Stem Cells
Background
EPH receptor B4 (EphB4), with 987-amino acid protein (about 108kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. The Eph receptor tyrosine kinases and their ligands, the ephrins, regulate numerous biological processes in developing and adult tissues and have been implicated in cancer progression and in pathological forms of angiogenesis. EphB4 acts as a negative regulator of blood vessel branching and vascular network formation, switching the vascularization program from sprouting angiogenesis to circumferential vessel growth. EphB4 and its ligand ephrinB2 express in several kinds of tumor cells and correlate with tumorigenesis. EphB4 is thus a potential candidate as a predictor of disease outcome in several kinds of tumor and as target for novel therapy.
Recommended Dilutions
WB.1/500 - 1/2000, IHC.1/200 - 1/1000, ELISA. Propose dilution 1/10000.
Formulation Description
Ascitic fluid containing 0.03% sodium azide.
CiteID
EN0013338

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug/100 ul
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close